Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women~* 18-35 years old~* Current collegiate or professional swimmer~* Currently training at least 300 minutes per week~* Self-reported to be healthy~Exclusion Criteria:~* Not within defined age range~* Current diagnosis of or using medication for:~  * Severe allergies~ * Asthma~ * Exercise-induced asthma~ * Exercise-induced bronchoconstriction~* Pulmonary function test considered to be abnormal (defined as forced vital capacity (FVC) \<80% of predicted, forced expiratory volume in one second (FEV1) \<80% predicted, and/or FEV1/FVC ratio \>5% of the predicted ratio)~* Hypertension during screening (systolic blood pressure \>139 or diastolic blood pressure \>89)~* Current tobacco or electronic cigarette use or consistent use within the last 2 years~* A contraindication for use of nedocromil sodium:~  * Previous adverse reaction to nedocromil sodium or a similar medication~ * Use of fast-acting, inhaled insulin~* A contraindication for use of cetirizine HCl:~  * Previous adverse reaction to cetirizine HCl or a similar medication~ * Allergy to the food additives E218 or E216~ * An intolerance to or inability to absorb some sugars, such as lactose or sorbitol~ * Liver or kidney failure~ * Epilepsy or similar condition~ * A condition that makes urinating difficult~ * Use of midodrine or ritonavir~* Are pregnant or could possibly be pregnant by self-report~* Subjects with current, irregular menstrual cycles (amenorrhea) or who had irregular menstruation patterns for greater than one year~* People who answer 'yes' to any of the pre-participation screening questions on page one of the PAR-Q+ questionnaire.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): This subset of 12 individuals will complete all experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents or 2) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion.
- Selection pool (Type: NO_INTERVENTION): Twenty-four total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (6 men, 6 women) will be a subset of the initial 24. The other 12 participants will not take part in further study.

Based on this trial design, predict the completion outcome and termination type (if applicable).